Steven L. Soignet, MD


Dr. Soignet is a co-founder of Arcus Ventures.  Before starting Arcus Ventures in 2007, Dr. Soignet was the Managing Director of The Arcus Group, a consulting company that provided due diligence and strategic guidance for financial service and pharma/biotech clients, which he co-founded in 2001.  Dr. Soignet also became a venture partner of Cross Atlantic Partners, a healthcare and biotechnology venture capital fund based in New York City, in 2003.

Prior to co-founding The Arcus Group, Dr. Soignet held a faculty appointment in the Developmental Chemotherapy Service at Memorial Sloan-Kettering Cancer Center, and in the Department of Medicine at Cornell University Medical Center. His primary research focus was in early phase clinical drug development in both hematological and solid tumors, which involved novel differentiation agents, transcription modulators, cell cycle inhibitors, monoclonal antibodies, vaccines, and cytotoxic chemotherapies. He was a lead investigator of a Pilot and a large US Multicenter Trial that led to the US FDA and European approval of arsenic trioxide for the treatment of relapsed acute promyelocytic leukemia. Dr. Soignet’s research has been published in the New England Journal of Medicine, Leukemia, Blood, Journal of Clinical Oncology and Clinical Cancer Research.

Dr. Soignet received his B.S. from the University of New Orleans, and his M.D. (AOA, honors) from Louisiana State University School of Medicine.  His internship and residency were completed in medicine at Vanderbilt University Medical Center and he then completed his fellowship training in medical oncology/hematology at Memorial Sloan-Kettering Cancer Center, where he subsequently joined the faculty. Dr. Soignet held several leadership positions at Memorial Sloan-Kettering Cancer Center, including Chief Fellow, Chairman of the Chemotherapy Practice, Vice-Chairman of the Pharmacy and Therapeutics Committee and a member of the Investigational New Drug committee. Dr. Soignet also served on the Board of Advisors of the American Red Cross, Greater New York Chapter.

Dr. Soignet was formerly a board observer on T2 Biosystems, Vascular Pathways, XTuit Pharmaceuticals, and he was a former member of the Board of Directors at Exosome Diagnostics.